I wanted to let you know about an important debate that's going on around health care reform that's been a bit under-the-radar. It's the issue of "biosimilars," which are medicines that are developed to mimic complex biologic drugs that treat diseases like cancer.
Howard Dean wrote an op-ed about the issue in The Hill today that lays out the case for an approach that strikes a balance -- it ensures fair prices and competition while also allowing the companies that...
]]>